Boston Scientific Gets Damages Reduced in Patent Case with Medtronic

Xconomy Boston — 

Boston Scientific (NYSE: BSX) said today it scored a victory with a U.S. District Court in Texas. A jury had previously determined the Natick, MA-based medical device company violated Medtronic’s patents on balloon catheters and stent delivery systems, awarding damages of $250 million. The court today found that two patents held by Medtronic (NYSE: MDT) were unenforceable, and it chose to reduce damages awarded to $19 million. Boston Scientific plans to appeal the remaining $19 million damage award to the U.S. Court of Appeals in Washington, and said it is “confident” it will win.